HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours By Ogkologos - July 30, 2025 433 0 Facebook Twitter Google+ Pinterest WhatsApp Real-world experience from pan-tumour testing Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR EMA Recommends Extension of Indications for Niraparib September 29, 2020 Androgen Receptor Pathway Inhibitors Outperform Taxanes in Patients with mCRPC with... September 6, 2024 Keeping progress in oncology on the agenda: ESMO honours recipients of... December 3, 2020 Saving Time for Patients and Improving Well-Being Through Mindfulness and Fitness:... October 23, 2023 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΤΟΥ ΠΝΕΥΜΟΝΑ:ΝΕΑ ΜΕΛΕΤΗ, ΝΕΕΣ ΕΛΠΙΔΕΣ Cancer Rehabilitation Starts at Diagnosis: Part II Rationale Explained for Granting EMA Authorisation for Extended Use of Nivolumab... Promising Results Demostrated with Novel Subcutaneously Adminstered Envafolimab in Patients with...
